In today’s briefing:
- Ohayo Japan | Tech Leads Market as S&P 500 Posts 4.6% Weekly Gain
- Japan Morning Connection: Rebound Continues with the SPX Clocking Its Best Run Since January
- CHMP Meeting Update April 2025: Sixteen New Medicines Recommended For Approval
Ohayo Japan | Tech Leads Market as S&P 500 Posts 4.6% Weekly Gain
- The S&P 500 closed higher by 0.7% and the Nasdaq Composite gained 1.3% on Friday.
- Advantest forecasts net sales of 755 billion yen, down 3%, and operating profit of 242 billion yen, up 6%, for the fiscal year ending March 2026
- Toyota Industries is considering going private via a takeover bid by a special purpose company (SPC) backed by Toyota and other group companies
Japan Morning Connection: Rebound Continues with the SPX Clocking Its Best Run Since January
- Tech and AI leading gains but the current rally feels like its running out of steam.
- Languid outlook from Advantest will not enthuse Japan SPE names.
- Shin Etsu blowing the doors off with a Y500bn buyback.
CHMP Meeting Update April 2025: Sixteen New Medicines Recommended For Approval
- EMA’s human medicines committee (CHMP) recommended sixteen medicines for approval at its April 2025 meeting. CHMP also adopted positive opinion for nine biosimilar medicines.
- Among the new medicines, Vertex’s triple combination cystic fibrosis drug Alyftrek, Amgen’s Thyroid eye disease drug Tepezza, and Jazz Pharmaceutical’s billiary tract cancer drug Ziihera have potential to become blockbusters.
- The Agency has recommended the refusal of the marketing authorization for Eli Lilly’s Alzheimer’s Disease drug Kisunla. Eli Lilly may ask for a re-examination of the opinion within 15 days.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
